TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1365471
Drug: 2.5% percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% percutaneous niflumic acid gel applied three times daily for 7 days
Study: 1365471
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied three times daily for 7 days
Study: 1365471
Drug: Niflumic acid
Normalized name: niflumic acid
DrugBank: Niflumic acid (DB04552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niflumic acid gel
Study: 235939
Drug: Ritodrine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine treatment
Study: 15937908
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg daily)
Study: 25306742
Drug: Itopride (Ganaton)
DrugBank: Itopride (DB04924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride (Ganaton) oral tablets 50 mg, 3 times daily for 8 weeks
Study: 23200288
Drug: Emotion Regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion Regulation Training (ERT) + Treatment as Usual (TAU)
Study: 18252070
Drug: Bio yogurt
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio yogurt (150 ml of live strawberry-flavoured yogurt for 12 days)
Study: 28905166
Drug: Self-help treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help treatment
Study: 25995055
Drug: IIH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIH treatment
Study: 21707766
Drug: Silodosin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin (8 mg/daily for a maximum of 8 weeks)
Study: 21707766
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drinking 2 L of water daily)
Study: 19772449
Drug: SC insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC insulin (regular human insulin or insulin lispro)
Study: 10905487
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg/day
Study: 11139307
Drug: Amifostine 740
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine 740 mg/m² immediately prior to chemotherapy
Study: 11139307
Drug: Amifostine with
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine with chemotherapy
Study: 9722203
Drug: Reinforced regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforced regimen (6 MU daily for 12 days, 6 MU thrice a week for 22 weeks, 3 MU thrice a week for 24 weeks)
Study: 7989961
Drug: Subgingival applications
Normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival applications of HPMC membranes containing 20% chlorhexidine and 40% doxycycline, applied twice a week for 6 weeks.
Study: 2498550
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term perioperative antibiotic (Group III)
Study: 2498550
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative antibiotic regimens (Group I and II)
Study: 2498550
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of penicillin and streptomycin (Group II)
Study: 30660196
Drug: Yerba mate
Normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yerba mate (YM) 1000 mL/day
Study: 30660196
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (GT) 1000 mL/day
Study: 30660196
Drug: Apple tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple tea (AT, control group) 1000 mL/day
Study: 28318997
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy (CEA) plus medical therapy
Study: 30265333
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.2 mg)
Study: 24997747
Drug: Periarticular multimodal
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular multimodal drug injection
Study: 21999886
Drug: Orodispersible escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orodispersible escitalopram (2 × 10 mg and 1 × 20 mg)
Study: 21999886
Drug: Conventional escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional escitalopram (2 × 10 mg)
Study: 17176206
Drug: Family treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family treatments combined with pharmacotherapy
Study: 8617070
Drug: Lower-intensity treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-intensity treatment (early mobilization and sustained maximal inflations)
Study: 8617070
Drug: Higher-intensity treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-intensity treatment (early mobilization, sustained maximal inflations, and single-handed percussions)
Study: 4078729
Drug: 96 mg
Normalized name: camphor 96 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 96 mg of cocaine (intranasal pretreatment)
Study: 4078729
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of cocaine (intranasal pretreatment)
Study: 4078729
Drug: Cocaine (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (i.v. injection after intranasal pretreatment)
Study: 4078729
Drug: Repeated administration
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated administration of cocaine
Study: 31050950
Drug: Home PBM
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home PBM treatments (n=4), administered three times per week for 12 weeks using the Vielight Neuro Gamma device.
Study: 30587368
Drug: Anti-MAdCAM antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-MAdCAM antibody (PF-00547659)
Study: 17654442
Drug: PKC-inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PKC-inhibitors
Study: 17654442
Drug: PPAR-alpha and
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPAR-alpha and -gamma agonists
Study: 17654442
Drug: Phosphodiesterase (PDE-5)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase (PDE-5) inhibitors
Study: 17654442
Drug: Statins plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins plus ACE inhibitors
Study: 15206277
Drug: Intraoperative autoblood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative autoblood reservation (7-8 ml/kg)
Study: 9672338
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.i.d. plus clarithromycin 500 mg b.i.d. (RBC-CLA)
Study: 9672338
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.i.d. plus tetracycline 500 mg q.i.d. plus metronidazole 500 mg t.i.d. (RBC-TET-MET)
Study: 9672338
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.i.d. plus amoxycillin 1000 mg b.i.d. plus clarithromycin 500 mg b.i.d. (RBC-AMO-CLA)
Study: 9672338
Drug: 14-day RBC
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day RBC 400 mg b.i.d. plus clarithromycin 500 mg b.i.d. (RBC-CLA)
Study: 7943693
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of mivacurium after complete recovery from > 95% neuromuscular block
Study: 7943693
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of mivacurium after 100 s exclusion from peak effect
Study: 31206749
Drug: Crestal implant
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crestal implant placement (Group-A)
Study: 31206749
Drug: Connective tissue
Normalized name: Connective tissue protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Connective tissue graft (CTG) over the implant neck (Group-B)
Study: 20214062
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment with alternative use of two groups of acupoints and electroacupuncture in disperse-dense wave for 30 min
Study: 7745071
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms gonadotrophin‐releasing hormone (GnRH)
Study: 7745071
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms GnRH agonist (GnRHa)
Study: 6118058
Drug: PGE‐2 aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE‐2 aerosol in alcohol solution
Study: 25526757
Drug: Intravaginal metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal metronidazole 750 mg plus miconazole 200 mg
Study: 21046988
Drug: Livina (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Livina (2 capsules twice daily) with ATT
Study: 17987463
Drug: Diluted diesel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted diesel exhaust (DE) inhalation (200 microg/m(3) of fine particulate matter)
Study: 15955903
Drug: Cumulative dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cumulative dexamethasone dose
Study: 8659761
Drug: Felodipine infusion
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine infusion
Study: 2223582
Drug: Tamoxifen (TM),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (TM), 30 mg per day for 2 years
Study: 7368968
Drug: Subcutaneous heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin, 5 000 IU twice daily
Study: 30411542
Drug: Non-intensive education
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-intensive education format (sequential 90-min tutorials delivered 1 week apart)
Study: 17326161
Drug: Sertraline (75-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (75-100 mg/day)
Study: 11035676
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (FM plus BUD)
Study: 11035676
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three treatments (FM, BUD, FM plus BUD)
Study: 8736460
Drug: Pinacidil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil (25 mg, orally)
Study: 1302543
Drug: Cang Dou
Normalized name: Cang zhu
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cang Dou Pill
Study: 3927691
Drug: Nicardipine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (average daily dosage 89 mg, range 40 to 160)
Study: 30606188
Drug: Opioid substitution
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid substitution treatment (OST)
Study: 31655598
Drug: OSCAR intervention
Normalized name: OsCal 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSCAR intervention (monthly structured interviews by Social Care Nurses)
Study: 20166794
Drug: Aripiprazole 10
Normalized name: aripiprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 10 mg/day
Study: 21823911
Drug: Aripiprazole 10
Normalized name: aripiprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 10 mg/day and 30 mg/day pooled
Study: 16719877
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg x kg(‐1)) with diphenhydramine (1.25 mg x kg(‐1))
Study: 16719877
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg x kg(‐1)) alone
Study: 15553109
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 3 mg phenprocoumon
Study: 28972854
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of carbohydrate drink (CHO)
Study: 26315481
Drug: Corticosteroid combined
Normalized name: combinations of corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid combined with oral tacrolimus (TAC, target trough blood concentration of 4‐8 ng/mL)
Study: 26315481
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (CYC, 750 mg/m(2)/mo)
Study: 26315481
Drug: Oral mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mycophenolate mofetil (MMF, 1.5‐2.0 g/d)
Study: 1677320
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg MK-467
Study: 1677320
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg MK-467
Study: 6869349
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg orally before meals and at bedtime
Study: 6869349
Drug: Conventional endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional endoscopic treatment (mechanical fragmentation and instillation of papain solution)
Study: 6869349
Drug: Long-term metoclopramide
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term metoclopramide treatment
Study: 31873985
Drug: Febuxostat (10‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (10‐40 mg)
Study: 31873985
Drug: Allopurinol (100‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (100‐200 mg)
Study: 27695944
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of 9 mg of sodium hyaluronate in 3 mL of a 0.9% sodium saline solution
Study: 27695944
Drug: Normal 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal 0.9% sodium chloride saline solution
Study: 25204290
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy based on traditional Chinese medicine (TCM) patterns including Bu‐Fei Jian‐Pi granules, Bu‐Fei Yi‐Shen granules, and Yi‐Qi Zi‐Shen granules along with conventional western medicine.
Study: 26909960
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine (control group).
Study: 21756153
Drug: CsA +
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA + CBD ointment
Study: 19617379
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 50 mg kg(‐1)
Study: 18154123
Drug: Intraoperative bolus-assisted
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative bolus-assisted administration of 5-fluorouracyl
Study: 7800739
Drug: 0.7 mg
Normalized name: naloxone 0.7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg nicotine cigarette
Study: 7800739
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg nicotine cigarette
Study: 7800739
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg nicotine cigarette (control)
Study: 7800739
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (0.1 mg, 0.7 mg, 1.5 mg)
Study: 7800739
Drug: 0.7 mg
Normalized name: naloxone 0.7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg and 1.5 mg groups
Study: 3142197
Drug: CQP 201-403
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQP 201-403 (0.05 mg to 0.035 mg)
Study: 3142197
Drug: CQP 201-403
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQP 201-403 (0.025 mg)
Study: 30977089
Drug: Chromium and
Normalized name: Cinnamon, Chromium and Biotin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium and carnitine co-supplementation (200 μg/day chromium picolinate plus 1000 mg/day carnitine)
Study: 28535933
Drug: Oseltamivir +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir + Azithromycin (500 mg/day for 5 days)
Study: 18341664
Drug: Topical retapamulin
Normalized name: retapamulin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retapamulin ointment 1% twice daily for 5 days
Study: 18341664
Drug: Topical retapamulin
Normalized name: retapamulin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retapamulin ointment 1%
Study: 2874823
Drug: ICI 162,846
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 162,846 0.5 mg
Study: 2874823
Drug: ICI 162,846
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 162,846 1.0 mg
Study: 2874823
Drug: ICI 162,846
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 162,846 2.5 mg
Study: 2874823
Drug: ICI 162,846
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 162,846 5.0 mg
Study: 24721143
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of motivational and volitional strategies to promote walking
Study: 23817284
Drug: MD.2 medication-dispensing
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD.2 medication-dispensing machine with care coordination
Study: 20639023
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy plus behavioral training (oxybutynin with pelvic floor muscle training and urge suppression techniques)
Study: 20639023
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy alone (oxybutynin)
Study: 20639023
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy plus behavioral training
Study: 20143047
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy alone
Study: 18685512
Drug: Probiotics and
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics and prebiotics treatment
Study: 16618656
Drug: Topical decongestants
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical decongestants (nafazoline and epinephrine)
Study: 14583062
Drug: Chronomodulated infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronomodulated infusion of oxaliplatin, fluorouracil and folinic acid
Study: 14583062
Drug: Fixed-rate infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed-rate infusion of oxaliplatin, fluorouracil and folinic acid
Study: 6084124
Drug: Hydrochlorothiazide (HCTZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ), 50 mg twice daily
Study: 6084124
Drug: Guanabenz, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanabenz, 4 to 32 mg twice daily
Study: 30065939
Drug: LH‐RHa therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH‐RHa therapy followed by a second orchidopexy
Study: 26395174
Drug: OLM/AML 40/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLM/AML 40/10 mg
Study: 24313633
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg daily for 8 weeks
Study: 11399215
Drug: Individual cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive-behavioral therapy
Study: 116537
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid infusion
Study: 8124481
Drug: Insulin (control)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (control)
Study: 2642566
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving immunotherapy)
Study: 21464152
Drug: Traditional rapid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional rapid palatal expansion and FM therapy
Study: 17312278
Drug: Portal vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portal vein embolization (PVE) + CD133(+) bone marrow stem cell (BMSC) administration
Study: 17312278
Drug: Portal vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portal vein embolization (PVE) + CD133(+) BMSC administration
Study: 8997547
Drug: Nicergoline 30
Normalized name: nicergoline 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline 30 mg b.i.d.
Study: 7967862
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (methronidazol and gentamicin, single preoperative dose)
Study: 2442993
Drug: Indecainide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indecainide (50 mg every 6 hours, increased to a maximum of 100 mg every 6 hours)
Study: 2442993
Drug: Quinidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (200 mg every 6 hours, increased to a maximum of 400 mg every 6 hours)
Study: 31539601
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Stress Management Mobile Health application (CBSM mHealth) - 10 weekly modules
Study: 15648985
Drug: Diclofenac 25
Normalized name: diclofenac 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 25 mg
Study: 14602746
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg) and vitamin D (400 IU) supplementation twice daily for 1 year
Study: 10799375
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of supplementation (1.67 MJ/d and 30 g protein/d)
Study: 3145752
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg terfenadine once daily
Study: 17138832
Drug: Carbohydrate ingestion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate ingestion (CHO) with 3 g/day L-carnitine